RNS Number : 1708S

BioPharma Credit PLC

12 March 2021

The announcement released on 11 March 2021 at 5.15pm under reference 0178S included an incorrect payment date in relation to the interim dividend.

The correct payment date is 16 April 2021.

The corrected announcement is set out below.




BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the financial period ending 31 December 2020 of $0.02040119 per ordinary share, payable on 16 April 2021 to ordinary shareholders on the register as at 19 March 2021. The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company.

The $0.02040119 return comprises an ordinary dividend of $0.0175 and a special dividend of $0.00290119. As a result, total dividends corresponding to the 2020 year totalled $0.07300119 per share.

The Company is currently paying and continues to target a 7 cent annual dividend per ordinary share.

The default payment for dividends is in US dollars. However, shareholders can elect to have dividends paid in sterling (GBP) and the option to elect a sterling dividend payment for this dividend will be available to shareholders until 19 March 2021 (the "Election Date").

Further details together with a copy of the Dividend Currency Election Form, which should be sent to Link Group, 10(th) Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL when completed, will be available on the Group's website shortly at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST.

LEI: 213800AV55PYXAS7SY24


Link Company Matters Limited

Company Secretary

12 March 2021



David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000


Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

March 12, 2021 12:00 ET (17:00 GMT)